« Study: Alcohol tied to 75,000 deaths a year in U.S. | Main | UCI scientists successfully target key HIV protein; breakthrough may lead to new drug therapi »

Costliest New Drugs Escape Patient, Insurer Revolt

By Kim Dixon and Ransdell Pierson

CHICAGO/NEW YORK (Reuters) - When it comes to the price tag for the newest biotechology drugs for cancer and other hard-to-treat diseases, the sky is likely to remain the limit, insurers, drugmakers and industry watchers say.

Neither HMOs nor the government-sponsored Medicare program is seriously challenging unprecedented costs for the new drugs, which include rheumatoid arthritis and multiple sclerosis treatments.

Article from: Reuters.com

TrackBack

TrackBack URL for this entry:
http://blog.lib.umn.edu/cgi-bin/mt-tb.cgi/593